CICC: Maintains "Outperform" rating on Sinopharm (01099.HK), target price HK$21.25; 1-3Q26 results in line with expectations

Zhitong Finance APP has learned that CICC released a research report stating that Sinopharm Group (01099.HK) achieved operating revenue of RMB 427.613 billion in the first three quarters of 2026, down 0.90% year on year; net profit attributable to shareholders was RMB 5.314 billion, up 0.13% year on year, and the results were in line with the bank's expectations. The bank maintained its net profit forecasts for the company for 2026 and 2027 at RMB 7.527 billion and RMB 7.918 billion, respectively, maintained the "Outperform" rating and a target price of HKD 21.25, corresponding to forecast price-to-earnings ratios of 7.6x and 7.0x for 2026 and 2027, respectively, implying 33.40% upside from the current share price.